Research theme

• Research and Development of New Prophylactic Vaccine Against Tuberculosis Using a Novel BCG-derived CTL-inducing Adjuvant with Tuberculosis Antigens.

Keywords

• BCG
• Adjuvant
• Cytotoxic T cell
• Tuberculosis Vaccine

Overview of Research

• BCG is currently the only licensed vaccine for tuberculosis (TB) and is effective against childhood TB and has contributed to its prevention for more than 100 years. However, the protective effect of BCG vaccine against adult pulmonary TB is limited. Complete Freud’s adjuvant, which contains killed Mycobacterium tuberculosis cells, exhibits excellent adjuvant activity, but cannot be used in humans due to safety concerns. It has been reported that various components of BCG can serve as adjuvants, but none have been put into practical use. BCG is currently the only licensed vaccine for tuberculosis (TB) and is effective against childhood TB and has contributed to its prevention for more than 100 years. However, the protective effect of BCG vaccine against adult pulmonary TB is limited.